Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
Brief Summary: The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma


Options:
A: Arm Label: FF 100mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Arm Label: FF 200mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily | Intervention Type: DRUG; Name: albuterol/salbutamol; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
C: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol
D: Arm Label: FS MDPI 200 / 12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: FS MDPI 100 / 12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Placebo MDPI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDPI, Drug: Albuterol/salmeterol HFA MDI | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100 / 12.5 mcg, FS MDPI 200 / 12.5 mcg | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: Placebo MDPI; Assigned to Arm(s): Placebo MDPI | Intervention Type: DRUG; Name: Albuterol/salmeterol HFA MDI; Assigned to Arm(s): FS MDPI 100 / 12.5 mcg, FS MDPI 200 / 12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg, Placebo MDPI

Answer: B